Posts in tag
Multispecific Antibodies
Cytovia Therapeutics Licenses Productivity-Boosting Manufacturing Technology for Its NK Engager Multifunctional Antibodies From ProteoNic
NEW YORK and LEIDEN, the Netherlands, Aug. 12, 2020 (GLOBE NEWSWIRE) — Cytovia Therapeutics, Inc (Cytovia), an emerging biopharmaceutical company developing CAR NK cell therapy and NK engager antibodies for cancer, announced today that it has licensed from ProteoNic BV its 2G UNic™ technology for boosting recombinant protein production, allowing for cost-effective manufacturing at large …